550 related articles for article (PubMed ID: 15659147)
41. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection.
Mulley WR; Hudson FJ; Tait BD; Skene AM; Dowling JP; Kerr PG; Kanellis J
Transplantation; 2009 Jan; 87(2):286-9. PubMed ID: 19155986
[TBL] [Abstract][Full Text] [Related]
42. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
[TBL] [Abstract][Full Text] [Related]
43. Treatment of acute glomerular rejection with FK 506.
Woodle ES; Spargo B; Ruebe M; Charette J
Clin Transplant; 1996 Jun; 10(3):266-70. PubMed ID: 8826664
[TBL] [Abstract][Full Text] [Related]
44. Refractory acute rejection in a living related liver transplantation.
Noritomi T; Sugawara Y; Kaneko J; Matsui Y; Makuuchi M
Hepatogastroenterology; 2003; 50(54):2192-3. PubMed ID: 14696495
[TBL] [Abstract][Full Text] [Related]
45. Anti-CD3 and -CD4 monoclonal antibody in the treatment of steroid-resistant renal allograft rejection.
Wang XH; Xie T
Chin Med J (Engl); 1993 Nov; 106(11):821-4. PubMed ID: 8143493
[TBL] [Abstract][Full Text] [Related]
46. Pharmacodynamics of rituximab in kidney transplantation.
Genberg H; Hansson A; Wernerson A; Wennberg L; Tydén G
Transplantation; 2007 Dec; 84(12 Suppl):S33-6. PubMed ID: 18162986
[TBL] [Abstract][Full Text] [Related]
47. ABO-incompatible deceased donor liver transplantation with the use of antigen-specific immunoadsorption and anti-CD20 monoclonal antibody.
Boberg KM; Foss A; Midtvedt K; Schrumpf E
Clin Transplant; 2006; 20(2):265-8. PubMed ID: 16640538
[TBL] [Abstract][Full Text] [Related]
48. Loss of a renal graft due to recurrence of anti-GBM disease despite rituximab therapy.
Sauter M; Schmid H; Anders HJ; Heller F; Weiss M; Sitter T
Clin Transplant; 2009; 23(1):132-6. PubMed ID: 19087095
[TBL] [Abstract][Full Text] [Related]
49. New insights into therapy with monoclonal antibodies in allograft transplantation.
Schena FP
Nephrol Dial Transplant; 1997; 12 Suppl 1():55-8. PubMed ID: 9075230
[No Abstract] [Full Text] [Related]
50. New immunosuppressive therapies in renal transplantation: monoclonal antibodies.
Buhaescu I; Segall L; Goldsmith D; Covic A
J Nephrol; 2005; 18(5):529-36. PubMed ID: 16299678
[TBL] [Abstract][Full Text] [Related]
51. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.
Tanriover B; Wright SE; Foster SV; Roush KS; Castillo-Lugo JA; Fa K; Levy FL; Mejia A
Transplant Proc; 2008 Dec; 40(10):3393-6. PubMed ID: 19100397
[TBL] [Abstract][Full Text] [Related]
52. Case 6: benefits and risks of OKT3 treatment in renal transplantation.
First MR
Transplantation; 2001 Sep; 72(6):1177-8. PubMed ID: 11584824
[No Abstract] [Full Text] [Related]
53. Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation.
Pascher A; Radke C; Dignass A; Schulz RJ; Veltzke-Schlieker W; Adler A; Sauer IM; Platz K; Klupp J; Volk HD; Neuhaus P; Mueller AR
Transplantation; 2003 Aug; 76(3):615-8. PubMed ID: 12923454
[TBL] [Abstract][Full Text] [Related]
54. Successful rescue of late-onset acute T-cell mediated rejection with anti-CD25 antibody: a case report.
Osawa T; Harada H; Miura M; Ogawa Y; Morooka K; Nakamura M; Tanabe T; Takada N; Seki T; Togashi M; Takenouchi T; Hirano T
Clin Transplant; 2009 Aug; 23 Suppl 20():31-3. PubMed ID: 19594593
[TBL] [Abstract][Full Text] [Related]
55. Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients.
Puissant-Lubrano B; Rostaing L; Kamar N; Abbal M; Fort M; Blancher A
Exp Clin Transplant; 2010 Mar; 8(1):19-28. PubMed ID: 20199367
[TBL] [Abstract][Full Text] [Related]
56. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
[TBL] [Abstract][Full Text] [Related]
57. Comparison of the acute rejection incidence rate in spousal donor transplantation before and after anti-CD20 antibody (rituximab) protocol as desensitization therapy.
Hirai T; Ishida H; Toki D; Miyauchi Y; Kohei N; Iida S; Tokita D; Shimizu T; Shirakawa H; Omoto K; Tanabe K
Ther Apher Dial; 2011 Feb; 15(1):89-97. PubMed ID: 21272258
[TBL] [Abstract][Full Text] [Related]
58. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection.
Khosroshahi HT; Tubbs RS; Shoja MM; Ghafari A; Noshad H; Ardalan MR
Transplant Proc; 2008; 40(1):137-9. PubMed ID: 18261569
[TBL] [Abstract][Full Text] [Related]
59. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome.
Yassa SK; Blessios G; Marinides G; Venuto RC
Clin Transplant; 2005 Jun; 19(3):423-6. PubMed ID: 15877809
[TBL] [Abstract][Full Text] [Related]
60. Antibody-mediated rejection with a striking interstitial monocyte/macrophage infiltration in a renal allograft under FTY720 treatment.
Sis B; Grynoch R; Murray AG; Campbell P; Solez K
Am J Kidney Dis; 2008 Jan; 51(1):127-30. PubMed ID: 18155542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
